Intimation of Transcript of Q1 FY 27 for the Earnings Conference Call held on July 20, 2026.

July 24, 2026 DCS-CRD Listing Compliance BSE Limited National Stock Exchange of India Limited First Floor, New Trade Wing Exchange Plaza, 5th Floor Rotunda Building, Phiroze Jeejeebhoy Towers Plot No. C/1, ‘G’ Block, Bandra- Kurla Dalal Street, Fort Mumbai 400001 Complex Bandra East Mumbai 400051 Fax No.2272 3121/2037/2039 Fax No.2659 8237/8238 Stock Code: 543213 Stock Code: ROSSARI Dear Sir/Madam, Sub.: Transcript of the Earnings Conference Call held on July 20, 2026 for Q1 FY27 Ref.: Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 Pursuant to the Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and with reference to our intimation dated July 14, 2026, regarding Earnings Conference call with Analyst(s)/Investor(s) held on Monday, July 20, 2026, we would like to inform that the transcript of the aforesaid conference call is enclosed herewith and the same is also available on the website of the Company at www.rossari.com/announcement under the head ‘Investor Call’. The same may please be taken on record and suitably disseminated to all concerned. Thanking you, Yours Sincerely, For Rossari Biotech Limited Parul Gupta Company Secretary & Head - Legal Membership No.: A38895 Encl.: as above Rossari Biotech Limited Q1 FY27 Earnings Conference Call Transcript July 20, 2026 Moderator: Ladies and gentlemen, good day and welcome to the Rossari Biotech Limited Earnings Conference Call. I now hand the conference over to Mr. Mitesh Jain from CDR India. Thank you and over to you, Mr. Jain. Mitesh Jain: Thank you, Swapnali. Good evening, everyone and thank you for joining us on Rossari Biotech Limited's Q1 FY27 earnings conference call. We have with us Mr. Edward Menezes, Promoter and Executive Chairman, Mr. Sunil Chari, Promoter and Managing Director, and Mr. Ketan Sablok, Group Chief Financial Officer of the company. We will begin the call with opening remarks from the management, following which we will have the forum open for a question-and-answer session. Before we start, I would like to point out that some statements made in today's call may be forward-looking in nature and a disclaimer to this effect has been included in the earnings presentation shared with you all earlier. I would now like to invite Mr. Edward Menezes to make his opening remarks. Over to you, sir. Edward Menezes: Thank you, Mitesh. Good evening, everyone and thank you for joining us on our earnings conference call. It is a pleasure to have you with us today as we discuss our operational and financial performance for the first quarter of FY2027. We commenced FY27 on a strong note, delivering our highest ever quarterly revenue and EBITDA, with consolidated revenue growing 28% YoY. The performance was supported by healthy momentum in the domestic business and the continued expansion of our international presence. Despite a dynamic operating environment, our diversified portfolio, extensive market research, and disciplined execution enabled us to deliver growth across our business segments. Page 1 of 16 Innovation remains central to our long-term strategy. The new R&D centre commissioned in the previous quarter is progressively ramping up, bringing our research, product development, and application capabilities together on an integrated platform. The facility is strengthening collaboration across teams, accelerating new product development, and supporting the faster scale-up and commercialization of differentiated technologies across end-user industries. Within our core HPPC segment, we continue to broaden our presence across higher value applications and strengthen our portfolio of specialty solutions. Our focus remains on expanding in areas such as personal care, pharmaceutical applications, agrochemicals, and performance chemicals, while leveraging our formulation expertise, application capabilities, and expanded manufacturing platform. The improving utilization of our ethoxylation capacities, together with a growing pipeline of new products, provides a strong foundation to scale this business further. During the quarter, we also strengthened our textile specialty chemicals portfolio through the launch of a dedicated Fibre Chemicals Division, expanding our capabilities across the fibre-to-fibre value chain. Supported by our application-driven R&D platform, deep formulation expertise, and manufacturing capabilities, the division enhances our ability to offer integrated value-added solutions and expand our addressable market within the textile industry. We remain encouraged by the long-term opportunity in the agrochemical sector, supported by increasing demand for advanced formulations, sustainable agricultural solutions, and productivity-enhancing inputs. With established capabilities across agro-surfactants, emulsifiers, and adjuvants, we are well-positioned to address evolving industry requirements through innovation-led specialty chemical solutions. As we progress through FY 2027, our priorities remain focused on fully leveraging the capabilities across the past few years, accelerating new product development, and enhancing operational efficiency. Supported by a healthy balance sheet, an integrated manufacturing platform, and an expanding innovation pipeline, we remain confident of delivering sustainable and profitable growth while creating long-term value for all our stakeholders. With this, I now invite Mr. Sunil Chari to share additional perspectives on our business performance and strategic priorities. Over to you, Chari. Sunil Chari: Thank you, Edward-ji, and a warm namaste to everyone. Page 2 of 16 As we approach the sixth anniversary of our listing, it is encouraging to reflect on Rossari's journey from an annual revenue base of around Rs. 600 crore to a business that has reached close to Rs. 700 crore in this quarter. This scale-up has been achieved through one of the most challenging periods in the company's history, encompassing the COVID-19 pandemic, unprecedented supply chain disruptions, raw material volatility, and geopolitical uncertainty. We believe we have navigated these challenges well, even as we continue to invest in capabilities, expand our portfolio, and strengthen the overall business platform. While the business has achieved significant scale, margins remain below their normalized potential. We have already initiated several measures to address this, including the monetization of our non-core assets, rationalization of lower margin businesses, improvement in product mix, and tighter cost discipline. As these initiatives progress over the next one to two years, alongside optimal utilization across our expanded capacities, we expect a meaningful strengthening in EBITDA performance. The quarter witnessed strong growth across each of our core business segments, with the HPPC, TSC, and AHN business all growing by around 28% YoY. Notably, the HPPC business crossed Rs. 550 crore quarterly revenue milestone, reflecting the increasing scale and depth of our presence across key applications and end- user industries. Our international business maintained its positive momentum, with exports growing 21% YoY during the quarter. The performance was supported by increasing wallet share with strategic partners, the addition of new customers, and wider acceptance of our specialty solutions across key overseas markets. We remain focused on deepening our presence in existing geographies while selectively expanding into markets that offer attractive long-term potential. During the quarter, we further strengthened our presence in Southeast Asia through a greenfield blending plant in Thailand. This facility will enhance our ability to offer customized formulations, respond faster to local market requirements, and improve supply chain efficiency. It also provides a platform to progressively expand our product offerings across [Showing first 8,000 characters — download PDF for full document]